Table 1

Selected basic patient characteristics*
Group A Group B
(XELIRI-Bev) (FOLFIRI-Bev)
N = 143 N = 142
Age
Median (range) 66 (28–84) 66 (32–80)
N (%) N (%)
<60 40 (28) 44 (31)
≥60 103 (72) 98 (69)
Gender
Male 79 (55) 92 (65)
Female 64 (45) 50 (35)
PS (ECOG)
0 92 (64) 94 (66)
1 37 (26) 40 (28)
2 12 (8) 6 (4)
Missing data 2 (2) 2 (2)
Primary location
Colon 98 (68) 85 (60)
Rectum 35 (25) 44 (31)
Rectosigmoid 3 (2) 8 (6)
Rectosigmoid and cecum 1 (1)
Misssing data 6 (4) 5 (3)
Stage at diagnosis
I 2 (1) 3 (2)
II 5 (4) 11 (8)
III 23 (16) 26 (18)
IV 107 (75) 90 (63)
Missing data 6 (4) 12 (9)
Previous adjuvant chemotherapy
No 114 (80) 112 (79)
Yes 27 (19) 27 (19)
Missing data 2 (1) 3 (2)
Previous surgery 114 (80) 123 (87)
Symptomatic disease
Yes 70 (49) 66 (46)
No 56 (39) 54 (38)
Missing data 17 (12) 22 (16)
Organs involved
Liver 103 (72) 101 (71)
Lung 51 (36) 39 (28)
Other 54 (38) 61 (43)
Number of organs involved
1 84 (59) 85 (60)
2 39 (27) 43 (30)
≥3 19 (13) 14 (10)
Missing data 1 (1)

*Pearson chi-square and Fisher’s exact tests were applied to compare patient characteristics (all p values above 0.05).

Pectasides et al.

Pectasides et al. BMC Cancer 2012 12:271   doi:10.1186/1471-2407-12-271

Open Data